Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XGN 
Exagen Inc (XGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: XGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.75
1 Year Target Price $7.75
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.16% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 152.59M USD | Price to earnings Ratio - | 1Y Target Price 7.75 |
Price to earnings Ratio - | 1Y Target Price 7.75 | ||
Volume (30-day avg) 6 | Beta 1.6 | 52 Weeks Range 1.71 - 7.95 | Updated Date 07/1/2025 |
52 Weeks Range 1.71 - 7.95 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -27.34% | Operating Margin (TTM) -21.71% |
Management Effectiveness
Return on Assets (TTM) -19.21% | Return on Equity (TTM) -117.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 164829106 | Price to Sales(TTM) 2.69 |
Enterprise Value 164829106 | Price to Sales(TTM) 2.69 | ||
Enterprise Value to Revenue 2.91 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 21860600 | Shares Floating 11084628 |
Shares Outstanding 21860600 | Shares Floating 11084628 | ||
Percent Insiders 19.82 | Percent Institutions 45.43 |
Analyst Ratings
Rating 3 | Target Price 7.75 | Buy - | Strong Buy 5 |
Buy - | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Exagen Inc
Company Overview
History and Background
Exagen Inc. was founded in 2002. It focuses on providing diagnostic and prognostic testing for autoimmune diseases, particularly rheumatology. It became a publicly traded company in 2019.
Core Business Areas
- Rheumatic Disease Diagnostics: Develops and commercializes diagnostic and prognostic tests for rheumatic diseases like rheumatoid arthritis, lupus, and Sju00f6gren's syndrome.
Leadership and Structure
Exagen Inc's leadership team includes the CEO, CFO, and other key executives overseeing various departments such as R&D, sales, and marketing. The company has a standard corporate structure with a board of directors.
Top Products and Market Share
Key Offerings
- AVISE CTD: A diagnostic test used to evaluate patients with suspected connective tissue diseases (CTDs). It aims to provide earlier and more accurate diagnoses. It is believed that Avise CTD is the main revenue source for Exagen Inc. Exact market share data is difficult to pinpoint, but competitors include companies offering similar diagnostic testing services and traditional diagnostic methods. The main competitors include LabCorp and Quest Diagnostics and other specialty labs that offer rheumatology testing.
- AVISE SLE: A diagnostic test that identifies systemic lupus erythematosus (SLE) patients. SLE is a chronic, autoimmune disease that can damage any part of the body (skin, joints, organs). There is no available market share data for the Avise SLE product. Competitors include LabCorp and Quest Diagnostics and other specialty labs that offer rheumatology testing.
Market Dynamics
Industry Overview
The autoimmune disease diagnostics market is growing, driven by increasing awareness, rising prevalence of autoimmune disorders, and technological advancements in diagnostic testing.
Positioning
Exagen Inc. is positioned as a specialty diagnostics company focused on improving the diagnosis and management of autoimmune diseases, differentiating itself through specialized testing and personalized medicine approaches.
Total Addressable Market (TAM)
The global autoimmune disease diagnostics market is estimated to be in the billions of dollars. Exagen Inc. is positioned to capture a portion of this TAM by providing specialized diagnostic solutions for rheumatic diseases. The expected total market value is between $7 and $10 billion US Dollars.
Upturn SWOT Analysis
Strengths
- Specialized expertise in autoimmune disease diagnostics
- Proprietary testing technologies
- Established relationships with rheumatologists
- Strong focus on R&D and innovation
Weaknesses
- Reliance on a limited number of key products
- Competition from larger diagnostic companies
- Reimbursement challenges from payers
- Limited financial resources compared to larger competitors
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic tests for other autoimmune diseases
- Partnerships with pharmaceutical companies
- Increasing awareness of the importance of early and accurate diagnosis
Threats
- Changes in reimbursement policies
- Increased competition from established diagnostic companies
- Technological advancements that could render existing tests obsolete
- Regulatory hurdles and compliance requirements
Competitors and Market Share
Key Competitors
- LH (LH)
- DGX (DGX)
Competitive Landscape
Exagen Inc. faces competition from larger, more established diagnostic companies. Its competitive advantage lies in its specialized focus on autoimmune disease diagnostics and its proprietary testing technologies. It however lacks the financial resources and scale of its largest competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth needs to be acquired for the company to determine the trends over the past years.
Future Projections: Future projections need to be acquired from analyst estimates to determine future projections.
Recent Initiatives: Recent initiatives need to be acquired to highlight the company's recent developments.
Summary
Exagen Inc is a specialty diagnostics company with a focus on autoimmune diseases, particularly rheumatology. Its strengths lie in its specialized expertise and proprietary testing technologies. However, it faces challenges from larger competitors, reimbursement pressures, and reliance on a limited product portfolio. The company's growth will depend on its ability to expand into new markets and develop innovative diagnostic solutions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
- Corporate Press Releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice. Market share estimates are approximations and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exagen Inc
Exchange NASDAQ | Headquaters Vista, CA, United States | ||
IPO Launch date 2019-09-19 | CEO, President & Director Mr. John Aballi | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 209 | Website https://www.exagen.com |
Full time employees 209 | Website https://www.exagen.com | ||
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.